These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2025306)

  • 21. Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology.
    Veale DJ; Reece RJ; Parsons W; Radjenovic A; O'Connor PJ; Orgles CS; Berry E; Ridgway JP; Mason U; Boylston AW; Gibbon W; Emery P
    Ann Rheum Dis; 1999 Jun; 58(6):342-9. PubMed ID: 10340958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
    Hepburn TW; Totoritis MC; Davis CB
    Rheumatology (Oxford); 2003 Jan; 42(1):54-61. PubMed ID: 12509613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis.
    Moreland LW; Pratt PW; Sanders ME; Koopman WJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S153-9. PubMed ID: 8100752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts.
    Moreland LW; Pratt PW; Bucy RP; Jackson BS; Feldman JW; Koopman WJ
    Arthritis Rheum; 1994 Jun; 37(6):834-8. PubMed ID: 7911664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
    Wendling D; Racadot E; Wijdenes J; Sibilia J; Flipo RM; Cantagrel A; Miossec P; Eschard JP; Macro M; Bertin P; Lioté F; Debiais F; Juvin R; Le Goff P; Masson C
    J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.
    van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM
    J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
    van der Lubbe PA; Dijkmans BA; Markusse HM; Nässander U; Breedveld FC
    Arthritis Rheum; 1995 Aug; 38(8):1097-106. PubMed ID: 7639806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.
    Tak PP; van der Lubbe PA; Cauli A; Daha MR; Smeets TJ; Kluin PM; Meinders AE; Yanni G; Panayi GS; Breedveld FC
    Arthritis Rheum; 1995 Oct; 38(10):1457-65. PubMed ID: 7575695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis.
    Horneff G; Sack U; Kalden JR; Emmrich F; Burmester GR
    Clin Exp Immunol; 1993 Feb; 91(2):207-13. PubMed ID: 7679058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis.
    Wendling D; Wijdenes J; Racadot E; Morel-Fourrier B
    J Rheumatol; 1991 Mar; 18(3):325-7. PubMed ID: 1713269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees.
    Jonker M; Slingerland W; Treacy G; van Eerd P; Pak KY; Wilson E; Tam S; Bakker K; Lobuglio AF; Rieber P
    Clin Exp Immunol; 1993 Sep; 93(3):301-7. PubMed ID: 8103714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.
    Yocum DE; Solinger AM; Tesser J; Gluck O; Cornett M; O'Sullivan F; Nordensson K; Dallaire B; Shen CD; Lipani J
    J Rheumatol; 1998 Jul; 25(7):1257-62. PubMed ID: 9676753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.
    Williams RO; Mason LJ; Feldmann M; Maini RN
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2762-6. PubMed ID: 7908442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics and human anti-mouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody.
    Choy EH; Schantz A; Pitzalis C; Kingsley GH; Panayi GS
    Br J Rheumatol; 1998 Jul; 37(7):801-2. PubMed ID: 9714366
    [No Abstract]   [Full Text] [Related]  

  • 35. [Anti-CD4 therapy in treatment of rheumatoid arthritis--have the die been cast?].
    Keysser G; Alpermann U; Burmester GR
    Z Rheumatol; 1998 Oct; 57(5):320-5. PubMed ID: 9864838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic use of a monoclonal, anti-CD4 antibody in refractory rheumatoid polyarthritis. Preliminary results].
    Wendling D; Wijdenes J; Racadot E
    Rev Rhum Mal Osteoartic; 1991 Jan; 58(1):13-7. PubMed ID: 1871515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of BWH-4 anti-CD4 monoclonal antibody on rat vascularized cardiac allografts before and after engraftment.
    Sayegh MH; Sablinski T; Tanaka K; Kut JP; Kwok CA; Tilney NL; Kupiec-Weglinski JW; Milford EL
    Transplantation; 1991 Feb; 51(2):296-9. PubMed ID: 1704648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children.
    Horneff G; Dirksen U; Schulze-Koops H; Emmrich F; Wahn V
    Ann Rheum Dis; 1995 Oct; 54(10):846-9. PubMed ID: 7492226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.
    Brett S; Baxter G; Cooper H; Johnston JM; Tite J; Rapson N
    Immunology; 1996 May; 88(1):13-9. PubMed ID: 8707338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.
    Scheerens H; Su Z; Irving B; Townsend MJ; Zheng Y; Stefanich E; Chindalore V; Bingham CO; Davis JC
    Arthritis Res Ther; 2011; 13(5):R177. PubMed ID: 22029963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.